Andrew E Teschendorff

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
    Andrew E Teschendorff
    Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R157. 2007
  2. ncbi High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
    Suet F Chin
    Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R215. 2007
  3. ncbi A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer
    Andrew E Teschendorff
    Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute, Cambridge, CB2 0RE, UK
    Breast Cancer Res 10:R73. 2008
  4. ncbi A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer
    Fabien Reyal
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 10:R93. 2008
  5. ncbi Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR
    Ian Roberts
    MRC Cancer Cell Unit, Hutchison MRC Research Centre, Hills Road, Cambridge, CB2 0XZ, UK
    BMC Biotechnol 8:57. 2008
  6. ncbi A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data
    Andrew E Teschendorff
    Department of Oncology, Cancer Genomics Program, Hutchison MRC Research Centre, University of Cambridge Hills Road, Cambridge CB2 2XZ, UK
    Bioinformatics 21:3025-33. 2005
  7. ncbi The breast cancer somatic 'muta-ome': tackling the complexity
    Andrew E Teschendorff
    Medical Genomics Group, Paul O Gorman Building, UCL Cancer Institute, University College London, London, UK
    Breast Cancer Res 11:301. 2009
  8. ncbi Elucidating the altered transcriptional programs in breast cancer using independent component analysis
    Andrew E Teschendorff
    Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
    PLoS Comput Biol 3:e161. 2007
  9. ncbi A consensus prognostic gene expression classifier for ER positive breast cancer
    Andrew E Teschendorff
    Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison MRC Research Center, Hills Road, Cambridge CB2 2XZ, UK
    Genome Biol 7:R101. 2006
  10. ncbi PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer
    Andrew E Teschendorff
    Cancer Genomics Program, Department of Oncology University of Cambridge, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, UK
    Bioinformatics 22:2269-75. 2006

Detail Information

Publications32

  1. ncbi An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
    Andrew E Teschendorff
    Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R157. 2007
    ..Reliable identification of ER-negative tumors that have a good prognosis is not yet possible...
  2. ncbi High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
    Suet F Chin
    Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R215. 2007
    ..To date, most genome-wide array comparative genomic hybridization studies have used tumor panels of relatively large tumor size and high Nottingham Prognostic Index (NPI) that are not as representative of breast cancer demographics...
  3. ncbi A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer
    Andrew E Teschendorff
    Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute, Cambridge, CB2 0RE, UK
    Breast Cancer Res 10:R73. 2008
    ..However, identification of such patients with a good prognosis remains difficult and at present is only possible through examining histopathological factors...
  4. ncbi A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer
    Fabien Reyal
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 10:R93. 2008
    ..we address the following issues: Do these signatures perform similarly? Are there (common) molecular processes reported by these signatures? Can better prognostic predictors be constructed based on these identified molecular processes?..
  5. ncbi Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR
    Ian Roberts
    MRC Cancer Cell Unit, Hutchison MRC Research Centre, Hills Road, Cambridge, CB2 0XZ, UK
    BMC Biotechnol 8:57. 2008
    ..We assessed a modified method, in which external calibration curves were generated from a single construct containing HPV16 E2, HPV16 E6 and the host gene hydroxymethylbilane synthase in a 1:1:1 ratio...
  6. ncbi A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data
    Andrew E Teschendorff
    Department of Oncology, Cancer Genomics Program, Hutchison MRC Research Centre, University of Cambridge Hills Road, Cambridge CB2 2XZ, UK
    Bioinformatics 21:3025-33. 2005
    ..We also compare the two criteria using freely available tumour microarray datasets and show that the variational Bayesian method is more sensitive to capturing biologically relevant structure...
  7. ncbi The breast cancer somatic 'muta-ome': tackling the complexity
    Andrew E Teschendorff
    Medical Genomics Group, Paul O Gorman Building, UCL Cancer Institute, University College London, London, UK
    Breast Cancer Res 11:301. 2009
    ....
  8. ncbi Elucidating the altered transcriptional programs in breast cancer using independent component analysis
    Andrew E Teschendorff
    Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
    PLoS Comput Biol 3:e161. 2007
    ..Adopting ICA as the analysis tool of choice will help understand the phenotype-pathway relationship and thus help elucidate the molecular taxonomy of heterogeneous cancers and of other complex genetic diseases...
  9. ncbi A consensus prognostic gene expression classifier for ER positive breast cancer
    Andrew E Teschendorff
    Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison MRC Research Center, Hills Road, Cambridge CB2 2XZ, UK
    Genome Biol 7:R101. 2006
    ..A consensus prognostic gene expression classifier is still elusive in heterogeneous diseases such as breast cancer...
  10. ncbi PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer
    Andrew E Teschendorff
    Cancer Genomics Program, Department of Oncology University of Cambridge, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, UK
    Bioinformatics 22:2269-75. 2006
    ..Feature selection methods that can identify relevant classifiers or that can remove likely false positives prior to supervised analysis are therefore desirable...
  11. ncbi Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus
    Christopher G Bell
    Medical Genomics, UCL Cancer Institute, University College London, London, United Kingdom
    PLoS ONE 5:e14040. 2010
    ....
  12. ncbi Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus
    Christopher G Bell
    Medical Genomics, UCL Cancer Institute, University College London, London, UK
    BMC Med Genomics 3:33. 2010
    ..Cases had T1D and nephropathy whereas controls had T1D but no evidence of renal disease...
  13. ncbi Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer
    Andrew E Teschendorff
    University College London, London WC1E 6BT, UK
    Genome Res 20:440-6. 2010
    ..These findings shed substantial novel insights into the epigenetic effects of aging and support the view that age may predispose to malignant transformation by irreversibly stabilizing stem cell features...
  14. ncbi BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines
    Ali Naderi
    Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison Medical Research Council Research Center, Hills Road, Cambridge, United Kingdom
    Cancer Res 67:6725-36. 2007
    ..These data suggest that a NGF/BEX2/NF-kappaB pathway is involved in regulating apoptosis in breast cancer cells and in modulating response to tamoxifen in primary tumors...
  15. ncbi Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors
    Andrew Feber
    Medical Genomics, UCL Cancer Institute, University College London, London, United Kingdom
    Genome Res 21:515-24. 2011
    ..This study establishes MeDIP-seq as an effective method to analyze cancer methylomes...
  16. ncbi Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer
    Miriam S Udler
    Strangeways Research Laboratory, Departments of Public Health and Primary Care and Oncology, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, United Kingdom
    Int J Cancer 125:2687-96. 2009
    ..These results suggest that COMT rs4818, or a variant it tags, is associated with breast cancer prognosis. Further study of COMT and its putative association with breast cancer prognosis is warranted...
  17. ncbi Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer
    Kerstin B Meyer
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge, United Kingdom
    PLoS Biol 6:e108. 2008
    ..We propose a model in which the Oct-1/Runx2 and C/EBPbeta binding sites in the disease-associated allele are able to lead to an increase in FGFR2 gene expression, thereby increasing the propensity for tumour formation...
  18. ncbi MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype
    Cherie Blenkiron
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R214. 2007
    ..MicroRNAs (miRNAs), a class of short non-coding RNAs found in many plants and animals, often act post-transcriptionally to inhibit gene expression...
  19. ncbi Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
    Caryn S Ross-Innes
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Nature 481:389-93. 2012
    ..By establishing transcription-factor mapping in primary tumour material, we show that there is plasticity in ER-binding capacity, with distinct combinations of cis-regulatory elements linked with the different clinical outcomes...
  20. ncbi Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules
    Andrew E Teschendorff
    Breast Cancer Functional Genomics Laboratory, Department of Oncology University of Cambridge, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    BMC Cancer 10:604. 2010
    ..However, relatively few strategies for estimating pathway activity from such model signatures exist and only few studies have used activation patterns of pathways to refine molecular classifications of cancer...
  21. ncbi Increased entropy of signal transduction in the cancer metastasis phenotype
    Andrew E Teschendorff
    Medical Genomics Group, Paul O Gorman Building, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK
    BMC Syst Biol 4:104. 2010
    ..However, relatively little is known as to what network features differ between the cancer and normal cell physiologies, or between different cancer cell phenotypes...
  22. ncbi Prognostic gene network modules in breast cancer hold promise
    Andrew E Teschendorff
    Medical Genomics Group, Paul O Gorman Building, UCL Cancer Institute, University College London, London WC1E 6BT, UK
    Breast Cancer Res 12:317. 2010
    ..We envisage that further improvements and insights may come from integrative expression pathway analyses that dissect prognostic signatures into modules related to cancer hallmarks...
  23. ncbi Independent surrogate variable analysis to deconvolve confounding factors in large-scale microarray profiling studies
    Andrew E Teschendorff
    Statistical Genomics Group, Paul O Gorman Building, UCL Cancer Institute, London WC1E 6BT, UK
    Bioinformatics 27:1496-505. 2011
    ..To deal with these difficulties, an algorithmic framework known as Surrogate Variable Analysis (SVA) was recently proposed...
  24. ncbi Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event
    Anna L Paterson
    Hutchison MRC Research Centre, Department of Pathology, University of Cambridge, Cambridge, UK
    Genes Chromosomes Cancer 46:427-39. 2007
    ..This article contains supplementary material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat...
  25. ncbi Differential expression of selected histone modifier genes in human solid cancers
    Hilal Ozdag
    Department of Oncology, Hutchison MRC Research Centre, University of Cambridge, Cambridge CB2 2XZ, UK
    BMC Genomics 7:90. 2006
    ..Expression of each gene in 225 samples (135 primary tumours, 47 cancer cell lines, and 43 normal tissues) was analysedby QRT-PCR, normalized with 8 housekeeping genes, and given as a ratio by comparison with a universal reference RNA...
  26. ncbi Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort
    Elizabeth M Azzato
    Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, UK
    Breast Cancer Res 10:R47. 2008
    ..Of particular interest are genes involved in cell cycle pathways, which regulate cell division...
  27. ncbi An epigenetic signature in peripheral blood predicts active ovarian cancer
    Andrew E Teschendorff
    Medical Genomics Group, University College London Cancer Institute, University College London, London, United Kingdom
    PLoS ONE 4:e8274. 2009
    ..However, to date no study has evaluated the diagnostic and predictive potential of such markers in a large case control cohort and on a genome-wide basis...
  28. ncbi The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer
    Joanna Zhuang
    Department of Women s Cancer, University College London Elizabeth Garrett Anderson Institute for Women s Health, London, UK
    PLoS Genet 8:e1002517. 2012
    ..These findings have major implications for cancer and embryonic stem cell biology and establish the importance of systemic DNA hypomethylation for predicting prognosis in a wide range of different cancers...
  29. ncbi Distribution of breakpoints on chromosome 18 in breast, colorectal, and pancreatic carcinoma cell lines
    Amber E Alsop
    Cancer Genomics Program, Hutchison-MRC Research Centre, Department of Pathology and Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, United Kingdom
    Cancer Genet Cytogenet 164:97-109. 2006
    ..We show that the latter is predicted by a simple model that invokes random breakage following anchorage of some random point on the chromosome, or selection of breaks proximal to one of several tumor suppressor genes...
  30. ncbi Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants
    M Trent Herdman
    Medical Research Council Cancer Cell Unit, Cambridge CB2 2XZ, UK
    Carcinogenesis 27:2341-53. 2006
    ..Greater emphasis should be placed on episome loss in models of HPV-related carcinogenesis. We provide the strongest evidence to date that treating HPV-16 lesions by inducing an IFN response may cause clinical progression...
  31. ncbi DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference
    Yan Jiao
    Statistical Genomics Group, Paul O Gorman Building, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK
    BMC Bioinformatics 12:403. 2011
    ..abstract:..
  32. ncbi ESR1 gene amplification in breast cancer: a common phenomenon?
    Lindsay A Brown
    Nat Genet 40:806-7; author reply 810-2. 2008